While discussing your acute lymphoblastic leukemia (ALL) treatment, your doctor may have talked to you about BLINCYTO®, an immunotherapy.1
BLINCYTO® is an immunotherapy that helps fight ALL. It is different from chemotherapy. BLINCYTO® works with your immune system to find and destroy cancer cells.1,2
In a study of 405 adults with relapsed or refractory ALL, BLINCYTO® was tested against commonly prescribed chemotherapy. It showed that common side effects of chemotherapy, including nausea and vomiting, showed up less often in adults treated with BLINCYTO®.1,3
Now let’s see how well BLINCYTO® worked in the study.
In the study, 271 people were treated with BLINCYTO® and 134 people were treated with chemotherapy.1
What’s more, when treated after first relapse, people on BLINCYTO® had a median survival of 11.1 months vs those on chemotherapy who had a median survival of 5.5 months.4
*Median overall survival is defined as the length of time from the start of treatment to when half of the patients in a treatment group are still alive.2
BLINCYTO® may cause serious side effects that can be severe or life-threatening. These include cytokine release syndrome (CRS), infusion reactions, and neurologic problems.
Tell your health care provider right away if you develop an infection or fever.
Tell your health care provider if you have any side effects that bother you or do not go away.
These are not all the possible side effects of BLINCYTO®.
What is the most important information I should know about BLINCYTO®?
Who should not receive BLINCYTO®?
What should I avoid while receiving BLINCYTO®?
Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:
BLINCYTO® (blinatumomab) is a prescription medication used to treat a certain type of acute lymphoblastic leukemia (ALL) in adults and children. ALL is a cancer of the blood and bone marrow in which a particular kind of white blood cell is replicating out of control.
References: 1. BLINCYTO® (blinatumomab) prescribing information, Amgen. 2. National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed October 9, 2019. 3. Data on file, Amgen; 2016. 4. Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60:2214-2222. 5. BLINCYTO® (blinatumomab) medication guide, Amgen.